Suchergebnisse - Cara Mathews

  • Treffer 1 - 2 von 2
Treffer weiter einschränken
  1. 1
    Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm

    Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based... von Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade

    Veröffentlicht 2023-09-01

    # Background Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite in...

    Ausführliche Beschreibung

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

    Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma von Stephanie Cham, Niya Xiong, Nabihah Tayob, Carolyn Krasner, Alexi A. Wright, Elizabeth K. Lee, Hannah Sawyer, Cara Mathews, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu

    Veröffentlicht 2025-08-01

    Purpose: Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to...

    Ausführliche Beschreibung

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: